奥妥珠单抗联合来那度胺治疗需全身治疗的晚期初治滤泡性淋巴瘤:一项LYSA研究
该2期GALEN研究纳入100例需全身治疗的晚期初治滤泡性淋巴瘤患者,给予奥妥珠单抗联合来那度胺诱导治疗6个周期,主要终点诱导后完全缓解率为47%,总缓解率92%。中位随访3.7年,3年无进展生存率和总生存率分别为82%和94%,最常见不良事件为中性粒细胞减少(任何级别48%,≥3级47%)。
要点
- 诱导后完全缓解率47%,总缓解率92%;按Lugano标准完全代谢缓解率80%,总缓解率94%。
- 中位随访3.7年,3年无进展生存率82%,总生存率94%。
- 中性粒细胞减少任何级别48%、≥3级47%,发热性中性粒细胞减少仅2%。
核心结论
- 对于高肿瘤负荷的初治滤泡性淋巴瘤患者,无化疗的GALEN方案显示出有前景的临床疗效。
- 除中性粒细胞减少外,该联合方案的安全性特征良好。
研究设计与样本
- 2期GALEN研究,纳入100例年龄≥18岁、ECOG体能状态≤2、高肿瘤负荷、1至3a级滤泡性淋巴瘤的初治患者。
- 诱导治疗为奥妥珠单抗(第1周期第8、15、22天,第2-6周期第1天,1000 mg静脉注射)联合来那度胺(第1周期第1-21天20 mg/天,第2-6周期第2-22天),共6个28天周期。
- 维持治疗为奥妥珠单抗(每2周期1000 mg)联合来那度胺(10 mg,第2-22天)≤12周期(第1年),随后奥妥珠单抗(每56天1000 mg)6周期(第2年)。
- 主要终点为诱导后按1999年国际工作组标准的完全缓解率。
- 研究于2015年10月至2017年2月入组,注册号NCT01582776。
主要发现
- 诱导后完全缓解率为47%,总缓解率为92%。
- 按2014年Lugano分类的事后分析(包括骨髓评估缺失的患者)额外识别13例符合完全缓解标准,完全代谢缓解率80%,总缓解率94%。
- 中位随访3.7年,3年无进展生存率82%,总生存率94%。
- 最常见不良事件为中性粒细胞减少(任何级别48%;≥3级47%);发热性中性粒细胞减少仅2%,其他主要为≤2级;无其他特定≥3级毒性发生率>3%。
关键数值与推荐
- 诱导后完全缓解率47%,总缓解率92%(1999年国际工作组标准)。
- 完全代谢缓解率80%,总缓解率94%(2014年Lugano分类事后分析)。
- 3年无进展生存率82%,总生存率94%(中位随访3.7年)。
- 中性粒细胞减少任何级别48%,≥3级47%;发热性中性粒细胞减少2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.
引用
- Bachy E, Houot R, Feugier P, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood. 2022. PMID: 34936697. doi:10.1182/blood.2021013526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。